XORTX Appoints Co-CEO, Details Path to NDA for Gout Drug XRx-026
XRTX sits 20% above its 52-week low of $1.725.
Summary
XORTX Therapeutics announced the appointment of Mika Grasso as Co-CEO for finance and public markets, alongside a detailed update on its lead gout drug program, XRx-026, outlining a clear path to NDA submission within 18 months.
Key Events · Product Development and Regulatory · XRTX
-
New Co-CEO Appointed
Mika Grasso has been appointed Co-CEO, responsible for finance and public markets. Mr. Grasso previously served as a director and has a background in investment management and banking.
-
Gout Program Advancement
The XRx-026 program for gout received clarifying feedback from the FDA regarding the remaining key steps for a New Drug Application (NDA) submission via the Section 505(b)(2) regulatory pathway.
-
Clinical Study Plan Detailed
The company is developing an Investigational New Drug (IND) application for XRx-026, which includes a proposed two-part clinical study to characterize pharmacokinetics and evaluate therapeutic equivalence.
-
Target Market and Timeline
The XRx-026 program targets a US $700 million per year market opportunity, with the company aiming for marketing approval within the next 18 months.
Analysis · XRTX · Life Sciences
The appointment of Mika Grasso as Co-CEO, specifically tasked with finance and public markets, signals a strategic focus on capital management and investor relations following a recent dilutive offering. Concurrently, the detailed update on the XRx-026 gout program, including positive FDA feedback, a clear IND development plan, and an 18-month target for marketing approval, provides a concrete path forward for the company's lead asset. This combination of strengthened leadership and tangible drug development progress is crucial for a micro-cap biotech that recently faced a going concern warning, indicating a proactive approach to leveraging new capital and advancing its pipeline.
At the time of this filing, XRTX was trading at $2.06 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $3.8M. The 52-week trading range was $1.73 to $7.05. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.